Physician profile
John M Cho
NPI 1659310332
$6,297.24
in general payments reported to CMS, 2019-2025
51 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $123 · 2021: $346 · 2022: $195 · 2023: $332 · 2024: $1,594 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,098 · Food and Beverage: $1,023 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,098.14 |
| Food and Beverage | $1,022.81 |
| Education | $310.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,292.39 | 2019-2025 | |
| Janssen Biotech, INC. | $446.66 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $343.19 | 2019-2025 | |
| Incyte Corporation | $314.82 | 2019-2024 | |
| Genentech USA, INC. | $242.51 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $215.88 | 2019-2023 | Provenge |
| Amgen INC. | $211.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $209.61 | 2019-2025 | Opdivo, Krazati |
| Seagen INC. | $192.31 | 2019-2023 | |
| Celgene Corporation | $186.01 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $174.44 | 2019-2024 | Enhertu |
| Glaxosmithkline, LLC. | $118.08 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $81.70 | 2019-2025 | Keytruda |
| Gilead Sciences, INC. | $77.97 | 2019-2025 | Trodelvy |
| Abbvie INC. | $77.31 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.